Gsk

The development comes at a time when US President Trump has announced fresh tariffs on global branded pharma majors, though GSK has said it plans to invest $30 billion in the United States over the next five years.

GSK’s profit outshines estimates as vaccines keep growing

The UK drugmaker’s best-selling shingles shot Shingrix as well as specialty medicines including drugs for asthma, HIV and cancer underpinned the brighter outlook

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults.

GSK plans to buy Canada's Bellus Health for $2 billion to expand on respiratory therapies

The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC)

Unilever CEO Alan Jope to retire at end of 2023 after GSK setback

Alan Jope, a long-term veteran of the consumer goods company, will leave after only five years in the role, with no named successor currently in place. The shares rose as much as 3.7% in early London trading.

GSK’s got heartburn that £50 billion could probably fix

Haleon, which is behind brands like Sensodyne toothpaste and Panadol painkillers, was a joint venture between GSK, the majority owner, and Pfizer Inc. until it gained independence through the July separation.

Telangana drug sleuths to crack down on large counterfeit drug cartels

There are some 30 players in all in the Indian market for hypothyroidism drugs, Abbott India’s Thyronorm leads the market with over 50% share, which is followed by Eltroxin from GSK and Thyrox from Macleods.

Sanofi, GSK Covid-19 vaccine found effective against Omicron

In a trial involving 13,000 adults, when given as a first dose the vaccine demonstrated an efficacy rate of 64.7% in people with symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

Pfizer to exit GSK's consumer health arm after spin-off

Pfizer previously signalled it would seek to sell its shareholding in Haleon, the world's largest consumer health business and home to Sensodyne toothpaste and Advil painkillers.

Unilever | Could the hunter become the hunted?

Unilever has attempted to justify its interest in acquiring GSK’s consumer healthcare business, but investors remain unhappy. Could this tip Unilever play into the M&A ring?

Lex | GSK: £50bn-plus takeover would leave Unilever omnileveraged

Unilever shareholders who feared the company lacked ambition may now worry it has too much fire in its belly

New data shows GSK-Vir drug works against all Omicron mutations

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

Sanofi, GSK get approval to conduct phase 3 trial of COVID-19 vaccine in India

In a two-stage approach, the phase 3 clinical study will initially investigate the efficacy of the COVID-19 vaccine formulation targeting the original novel coronavirus strain.

COVID-19 vaccine | Sanofi to seek permission for Phase 3 trial in India: Report

Sanofi is looking to conduct a part of its 35,000-participant global Phase 3 trial of its COVID-19 vaccine in India.

COVID-19 Vaccine | Sanofi and GSK’s vaccine said to produce strong immune responses in mid-stage study

The vaccine hit a major setback in December, when its developers announced that it did not appear to work well in older adults and that they would have to delay plans to test it in a Phase 3 trial, the crucial test that will assess the vaccine’s effectiveness.

Meet Sudhir Sitapati, Godrej consumer’s new top boss

GCPL’s stock soared the most since it went public following the announcement of the new Managing Director and CEO, Sudhir Sitapati – an HUL veteran.

Glenmark Pharma’s Kaizad Hazari to become General Counsel of Arcelor Mittal Nippon Steel India; Ex- Dr Reddy’s Suprio Dasgupta to replace Hazari

Kaizad Hazari has more than 28 years of experience and has previously worked with HDFC Ltd, GSK, Hindalco Industries, Raymonds, Asian Paints and ICICI Bank. Prior to Dr Reddy’s, Dasgupta, an alumnus of the NLSIU Bangalore 1994 LLM batch, has had stints at Schneider Electric, International Paper , Honeywell International, General Electric and the United Nations High Commission for Refugees.

GSK, Sanofi begin new COVID-19 vaccine trial after setback last year

The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.

GSK, CureVac partnership eyes COVID-19 vaccine against multiple variants

In a joint statement on Wednesday, the partners said they were targeting a possible launch in 2022.

GSK, Sanofi to make 200 million doses available for COVID-19 vaccine alliance

COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan.

GlaxoSmithKline to launch late-stage testing of syncytial virus vaccine

RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years.

Sanofi and GSK launch trial for COVID-19 protein-based vaccine

Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.

Sanofi, GSK to supply up to 60 million doses of COVID-19 vaccine to UK

Financial terms of the agreement were not disclosed. Sanofi and GSK, which had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was to be positive.

Britain's GSK to take 10% stake in Germany's CureVac for $163 million

CureVac's existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.

COVID-19 vaccine | Britain nears 500 million pound deal with GSK, Sanofi: Report

Britain is considering an option to buy the vaccine if human trials, which are due to begin in September, are successful.